Life Technologies’ Ion Proton™ Sequencer Receives San Diego’s CONNECT Most Innovative New Product Award
CARLSBAD, Calif., Dec. 7, 2012 -- Life Technologies Corporation announces that its Ion Proton™ Sequencer has been honored at the 25th annual Most Innovative New Product “MIP” Awards luncheon hosted by CONNECT in San Diego today. The judges recognized the DNA and RNA sequencing instrument for its disruptive semiconductor-based technology.
The platform’s speed, ease-of-use and affordability are democratizing genome sequencing. For the first time, genome-scale sequencing is accessible to all scientists and medical researchers, enabling an unprecedented wave of innovation in life sciences and the advancement of clinical research.
Until now, genome-scale sequencing had only been possible at large centers or core labs because it required specialized molecular biology skills, expensive sequencers, extensive IT infrastructure and large numbers of bioinformatics specialists. The Ion Proton™ System helps overcome all of these barriers, enabling scientists to sequence affordably on the bench top in their own labs.
“Speed, scalability and simplicity has always been at the core of the Ion Proton System,” said Gina Costa, Research and Development Leader, Molecular Biology, Ion Torrent Genetics Analysis, who accepted the award in the Life Sciences — Diagnostics and Research Tools category. “I and the Ion Torrent team at Life Technologies are honored to be recognized for an instrument that is beginning to have a major impact in the genetic analysis field.”
A semiconductor chip is at the heart of the Ion Proton’s technology. Instead of relying on light-based technology and cameras to capture images of DNA sequences, the Ion Proton™ System translates chemical information into digital data. The chip enables sequencing to be performed on a massively parallel format, drastically accelerating the sequencing process.
CONNECT is a regional organization that promotes and facilitates the development of innovative technology and life science products in San Diego. It was originally founded as part of University of California at San Diego in 1985 and has since helped develop more than 3,000 companies by creating networking opportunities between inventors and entrepreneurs.
The Ion Proton™ Sequencer is for research use only; Not intended for diagnostic purposes.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today’s most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011.
Visit us at our website: www.lifetechnologies.com.
Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact